Back to search results

Understanding Topical CBD and THC Absorption

This study is looking at how your body absorbs cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) when applied to the skin in a hemp-based lotion. Researchers want to see how much of these substances get into your system after using the lotion once and over several days. They will measure the levels of CBD and THC in your oral fluid (spit) to understand this. You might be able to join if you are between 18 and 55 years old, in good health, and have not recently used cannabis. The study aims to understand how these topical products are processed by the body. The current recruitment status is unclear.

Study design
This is an interventional study with 6 participants. It is not specified if it is randomized or blinded.
What's involved
You would participate in a 7-day residential stay where the lotion is applied four times daily. Oral fluid, blood, and urine samples will be collected, and you will return after a 7-day break for more oral fluid collections.
Compensation
Not stated in the trial record.
Follow-up
You will return after a 7-day washout period to provide additional oral fluid samples.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07603518

The Pharmacokinetics of a Hemp-Based Topical Product

Recruiting
PHASE1Ages 18–55InterventionalBasic science
Johns Hopkins University
~20 participants
Updated 2026-09-03 on ClinicalTrials.gov
What's tested:CBDTHC

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in concentration of oral fluid cannabinoids
Measured over Days 1-7 and Day 14

Conditions

Cannabis

Explore related trials

Healthy Volunteers

NCT07603518

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Behavioral Pharmacology Research Unit

    Baltimore, Marylandno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Tory Spindle, PhD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Lizzie Wilkerson
[email protected]
4105500529
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have provided written informed consent
Be between the ages of 18 and 55
Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
Test negative for recent cannabis use in urine at the screening visit and again upon admission for the inpatient stay.
Test negative for other drugs of abuse, including alcohol, at the screening visit and again upon admission for the inpatient stay.
Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit.
Have a body mass index (BMI) in the range of 18 to 38 kg/m2
Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
Report prior experience using cannabis or CBD products.

Exclusion

Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit.
History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
Current use of medications which, in the opinion of the investigator or medical monitor, will interfere with the study results or the safety of the subject.
History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.
Known allergy to any ingredients in the study drug.
Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.

What this trial measures

  • Change in concentration of oral fluid cannabinoidsDays 1-7 and Day 14

    Concentration of cannabinoids will be measured in oral fluid (unit of measurement: nanograms/mL)